XML 37 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Business Segments
 6 Months Ended
Jun. 30, 2012
Segment Reporting [Abstract]  
Business Segments
 
 
Note 8. Business Segments
 
The Company maintains two active business segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.
 
   
Three Months Ended
June 30,
  
   
2012
    
2011
  
Revenues, Principally from Grants
            
Vaccines/BioDefense
   $ 710,237     $ 335,029  
BioTherapeutics
     52,614       70,791  
  Total
   $ 762,851     $ 405,820  
                 
Loss from Operations
                
Vaccines/BioDefense
   $ (2,144 )   $ (67,425 )
BioTherapeutics
     (481,817 )     (1,663,402 )
Corporate
     (497,716 )     (201,963 )
  Total
   $ (981,677 )   $ (1,932,790 )
 
Amortization and Depreciation Expense
                
Vaccines/BioDefense
   $ 24,954     $ 10,183  
BioTherapeutics
     25,892       43,290  
Corporate
     562       542  
  Total
   $ 51,408     $ 54,015  
                 
Interest Income, Net 
                
Corporate 
   $ 1,799     $ 1,473  
                 
Stock-Based Compensation
                
Vaccines/BioDefense
   $ 2,130     $ 18,416  
BioTherapeutics 
     56,194       188,255  
Corporate 
     59,064       25,198  
   Total 
   $ 117,388     $ 231,869  
 
   
Six Months Ended
June 30,
  
   
2012
    
2011
  
Revenues, Principally from Grants
            
Vaccines/BioDefense
   $ 1,307,842     $ 871,615  
BioTherapeutics
     102,427       342,210  
  Total
   $ 1,410,269     $ 1,213,825  
                 
Income (Loss) from Operations
                
Vaccines/BioDefense
   $ (130,509 )   $ 52  
BioTherapeutics
     (1,207,859 )     (3,044,729 ) 
Corporate
     (1,084,299 )     (610,959 ) 
  Total
   $ (2,422,667 )   $ (3,655,636 )
 
Amortization and Depreciation Expense
                
Vaccines/BioDefense
   $ 52,951     $ 19,872  
BioTherapeutics
     54,733       84,491  
Corporate
     1,069       1,080  
  Total
   $ 108,753     $ 105,443  
                 
Interest Income, Net 
                
Corporate 
   $ 4,034     $ 3,908  
                 
Stock-Based Compensation
                
Vaccines/BioDefense
   $ 4,260     $ 36,832  
BioTherapeutics 
     112,614       286,508  
Corporate
     118,128       65,296  
   Total
   $ 235,002     $ 388,636  
 
 
   
As of
June 30,
 2012
    
As of
December 31,
2011
  
             
Identifiable Assets
            
Vaccines/BioDefense
   $ 557,211     $ 689,266  
BioTherapeutics
     658,593       753,767  
Corporate
     4,695,661       6,780,625  
  Total
   $ 5,911,465     $ 8,223,658